Research and Markets (http://www.researchandmarkets.com/research/tt9stb/avastin) has announced the addition of the "Avastin (Colorectal Cancer) - Forecast and Market Analysis to 2023" report to their offering.
Avastin was the first agent of a new class of drugs that targeted the angiogenesis pathway. The anti-angiogenic agent is a humanized monoclonal IgG1 that binds to vascular endothelial growth factor-A (VEGF-A), preventing the ligand from binding to the VEGF receptor. Inhibition of the VEGF pathway prevents endothelial cells from proliferating and forming the new bloods vessels that are required for the tumor to grow. The drug delivered as a monotherapy is not curative, and must be co-administered with a chemotherapy regimen.
Scope
- Overview of Colorectal Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Avastin including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Avastin for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China.
Key Topics Covered:
1 List of Tables
2 Introduction
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Avastin (Bevacizumab)
7 Appendix
For more information visit http://www.researchandmarkets.com/research/tt9stb/avastin
